Intensity Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 17
- Market Cap
- $59.2M
- Introduction
Intensity Therapeutics, Inc. operates as biotechnology company which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in ...
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Intensity Therapeutics, Inc.
- Target Recruit Count
- 333
- Registration Number
- NCT06263231
- Locations
- 🇺🇸
The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇩🇪Helios Klinikum Bad Saarow, Bad Saarow, Germany
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
- First Posted Date
- 2017-02-20
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Intensity Therapeutics, Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT03058289
- Locations
- 🇺🇸
USC Norris, Los Angeles, California, United States
🇺🇸USC HOAG, Newport Beach, California, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
© Copyright 2024. All Rights Reserved by MedPath